Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials

To investigate the cause of visual acuity (VA) loss in patients with neovascular age-related macular degeneration (AMD) receiving monthly ranibizumab injections in the pivotal ranibizumab phase III trials. Retrospective analysis. The Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizum...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Ophthalmology (Rochester, Minn.) Ročník 118; číslo 3; s. 523
Hlavní autori:	Rosenfeld, Philip J, Shapiro, Howard, Tuomi, Lisa, Webster, Mary, Elledge, Julee, Blodi, Barbara
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.03.2011
Predmet:	Angiogenesis Inhibitors - administration & dosage Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Choroidal Neovascularization - drug therapy Choroidal Neovascularization - physiopathology Fluorescein Angiography Humans Intravitreal Injections Macular Degeneration - drug therapy Macular Degeneration - physiopathology Ranibizumab Retinal Pigment Epithelium - pathology Retrospective Studies Risk Factors Tomography, Optical Coherence Vascular Endothelial Growth Factor A - antagonists & inhibitors Vision Disorders - physiopathology Visual Acuity - physiology
ISSN:	1549-4713, 1549-4713
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!